Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Immune checkpoint inhibitors, such as programmed death 1 (PD-1) and programmed cell
death-Ligand 1 (PD-L1), offer new approaches for systemic treatment of tumors, but clinical
efficacy remains limited. Previous studies by our team have found that methotrexate can
activate anti-tumor immunity. The discovery of a new effect of this drug will improve tumor
response to immunotherapy and prognosis of patients.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Institute of Materia Medica, Chinese Academy of Sciences